ALLOMICROVACProject reference: 36928
Funded under :
A combined microbicidal-immunizing strategy against SIV and HIV infection
Total cost:EUR 1 268 568
EU contribution:EUR 1 100 000
Coordinated in:United Kingdom
Topic(s):LSH-2005-2.3.0-4 - New approaches for research into host/vector-pathogen interaction for HIV/AIDS, malaria and tuberculosis
Call for proposal:FP6-2005-LIFESCIHEALTH-6See other projects for this call
Funding scheme:STREP - Specific Targeted Research Project
The objective of the proposed project is to establish proof of concept that a tri-molecular construct, consisting of MHC antigens combined with microbial HSP70 and extracellular CCR5 can be utilized in microbicidal, preventive and therapeutic immunisation. This strategy utilizes a novel microbicidal construct to protect against mucosal SHIV infection in female macaques.
However, as the construct is immunogenic, repeated applications will elicit mucosal, regional and systemic immunity. The preventive strategy is based on two 'experiments of nature', alloimmunity and homozygous '32 CCR5 mutation. The microbicidal-immunogenic agent elicits innate antiviral responses and targets different stages in the infectious process. Investigation of the three preventive modalities are outlined below.
- To select 3 common macaque MHC molecules (Mamu A1,A4,A8), expressed as novel Dextramer constructs, to inhibit mucosal transmission of SHIV.